Retinopathy of prematurity (ROP) is a bilateral retinal disorder that occurs in babies born prematurely. It is characterized by abnormal neovascularization, scarring, and retinal detachment that may progress to significant vision loss or blindness. The condition ranges in severity from mild to severe. Causes documented in this packet include oxygen toxicity and hypoxia. No genetic basis or inheritance pattern is established in this packet, consistent with the acquired nature of this condition. General population prevalence is estimated at approximately 1 to 5 per 10,000 individuals.

Phenotype-level data is not available in this packet. The defining clinical features include bilateral neovascularization, retinal scarring, and retinal detachment. Outcomes range from mild retinal changes to severe bilateral vision loss or complete blindness. Severity varies among affected infants.

Retinopathy of prematurity occurs in premature infants. Causes documented in this packet include oxygen toxicity and hypoxia. No specific genetic cause or inheritance pattern is established in this packet, consistent with the acquired, non-heritable nature of this condition.

Specific diagnostic methods are not detailed in this packet.

Three FDA-approved formulations of aflibercept are listed in this packet: EYLEA (aflibercept, BLA, approved 2011), EYLEA HD (aflibercept, BLA, approved 2023), and EYDENZELT BOAV (aflibercept, BLA, approved 2025), all with active market status. These represent biologic therapies with FDA approval for retinopathy of prematurity. Numerous additional treatments are under active investigation in clinical trials.

Prognosis data is not available in this packet. The condition may result in blindness and ranges from mild to severe, as documented in the definition.

Retinopathy of prematurity is an active research area with numerous ongoing clinical trials currently enrolling participants. Active investigations span interventional and observational designs, including studies of anti-VEGF therapy protocols, pharmacological approaches for prevention, pain management during screening procedures, and long-term outcome tracking in premature infant populations. Both academic and industry sponsors are represented in the active trial portfolio.